WuXi AppTec expands to create a center of excellence in San Diego

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/s-c-s)
(Image: Getty/s-c-s)

Related tags Wuxi apptec Small molecule Manufacturing Pharmacology discovery services

The expansion collates WuXi AppTec’s technology platform small molecule capabilities, including screening, discovery biology, pharmacology, and process R&D.

The San Diego, CA-based facility – now a new center of excellence – also provides Phase I good manufacturing practice (GMP) manufacturing services.

WuXi AppTec​ Chairman and CEO Dr. Ge Li said the expansion will enable the company to better serve its US and global customers.

"Together with our ecosystem partners, we will continue to strengthen WuXi's capability and technology enabling platform to expedite the discovery and development of new medicines for patients worldwide,”​ Li said in a press release.

As part of the expansion, the contract research organization (CRO) also plans to hire “extensively”​ from around the San Diego area.

WuXi AppTec was unable to provide any further comment.

IPO and expansion

To build and expand its R&D facilities, the company earlier this year raised more than $353​ in an initial public offering (IPO) of common stock.

WuXi AppTec's IPO of 104,198,600 shares of common stock was offered on the Shanghai Stock Exchange at RMB21.60 per share. This, equivalent to US$3.39 per share, means the IPO has brought in more than $353m.

The company has completed expansions at several of its subsidiary companies, including STA Pharmaceutical​.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers